These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 18025893)

  • 1. Association between specific enfuvirtide resistance mutations and CD4 cell response during enfuvirtide-based therapy.
    Melby TE; Despirito M; Demasi RA; Heilek G; Thommes JA; Greenberg ML; Graham N
    AIDS; 2007 Nov; 21(18):2537-9. PubMed ID: 18025893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment.
    Aquaro S; D'Arrigo R; Svicher V; Perri GD; Caputo SL; Visco-Comandini U; Santoro M; Bertoli A; Mazzotta F; Bonora S; Tozzi V; Bellagamba R; Zaccarelli M; Narciso P; Antinori A; Perno CF
    J Antimicrob Chemother; 2006 Oct; 58(4):714-22. PubMed ID: 16891628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cohort study of enfuvirtide immunological and virological efficacy in clinical practice.
    Bienvenu B; Krivine A; Rollot F; Pietri MP; Lebault V; Meritet JF; Guerin C; Spiridon G; Salmon D; Guillevin L; Lebon P; Launay O
    J Med Virol; 2006 Oct; 78(10):1312-7. PubMed ID: 16927284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virological fitness of HIV in patients with resistance to enfuvirtide.
    Chibo D; Roth N; Roulet V; Skrabal K; Gooey M; Carolan L; Nicholls J; Papadakis A; Birch C
    AIDS; 2007 Sep; 21(14):1974-7. PubMed ID: 17721108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen.
    Deeks SG; Lu J; Hoh R; Neilands TB; Beatty G; Huang W; Liegler T; Hunt P; Martin JN; Kuritzkes DR
    J Infect Dis; 2007 Feb; 195(3):387-91. PubMed ID: 17205477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment.
    Menzo S; Castagna A; Monachetti A; Hasson H; Danise A; Carini E; Bagnarelli P; Lazzarin A; Clementi M
    New Microbiol; 2004 Apr; 27(2 Suppl 1):51-61. PubMed ID: 15646065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
    Lalezari JP; Henry K; O'Hearn M; Montaner JS; Piliero PJ; Trottier B; Walmsley S; Cohen C; Kuritzkes DR; Eron JJ; Chung J; DeMasi R; Donatacci L; Drobnes C; Delehanty J; Salgo M;
    N Engl J Med; 2003 May; 348(22):2175-85. PubMed ID: 12637625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamics of enfuvirtide resistance mutations in enfuvirtide-experienced patients remaining in virological failure under salvage therapy.
    Charpentier C; Jenabian MA; Piketty C; Karmochkine M; Tisserand P; Laureillard D; Bélec L; Si-Mohamed A; Weiss L
    Scand J Infect Dis; 2011 May; 43(5):373-9. PubMed ID: 21341978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unexpected dramatic increase in CD4+ cell count in a patient with AIDS after enfuvirtide treatment despite persistent viremia and resistance mutations.
    Soria A; Cavarelli M; Sala S; Alessandrini AI; Scarlatti G; Lazzarin A; Castagna A
    J Med Virol; 2008 Jun; 80(6):937-41. PubMed ID: 18428138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viral failure in HIV-infected patients with long-lasting viral suppression who discontinued enfuvirtide.
    Bonjoch A; Negredo E; Puig J; Erkizia I; Puig T; Cabrera C; Ruiz L; Clotet B
    AIDS; 2006 Sep; 20(14):1896-8. PubMed ID: 16954734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
    Lazzarin A; Clotet B; Cooper D; Reynes J; Arastéh K; Nelson M; Katlama C; Stellbrink HJ; Delfraissy JF; Lange J; Huson L; DeMasi R; Wat C; Delehanty J; Drobnes C; Salgo M;
    N Engl J Med; 2003 May; 348(22):2186-95. PubMed ID: 12773645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment.
    Menzo S; Castagna A; Monachetti A; Hasson H; Danise A; Carini E; Bagnarelli P; Lazzarin A; Clementi M
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3253-9. PubMed ID: 15328081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1-infected patients from the French National Observatory experiencing virological failure while receiving enfuvirtide.
    Descamps D; Assoumou L; Masquelier B; Marcelin AG; Saidi S; Tamalet C; Cottalorda J; Plantier JC; Montes B; Izopet J; Peytavin G; Yerly S; Schneider V; Delaugerre C; Ferré V; Ruffault A; Pallier C; Morand-Joubert L; Chaix ML; Calvez V; Brun-Vézinet F; Costagliola D;
    J Antimicrob Chemother; 2008 Sep; 62(3):451-5. PubMed ID: 18552344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure.
    Poveda E; Rodés B; Labernardière JL; Benito JM; Toro C; González-Lahoz J; Faudon JL; Clavel F; Schapiro J; Soriano V
    J Med Virol; 2004 Sep; 74(1):21-8. PubMed ID: 15258964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen.
    Cabrera C; Marfil S; García E; Martinez-Picado J; Bonjoch A; Bofill M; Moreno S; Ribera E; Domingo P; Clotet B; Ruiz L
    AIDS; 2006 Oct; 20(16):2075-80. PubMed ID: 17053353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure.
    Svicher V; Aquaro S; D'Arrigo R; Artese A; Dimonte S; Alcaro S; Santoro MM; Di Perri G; Caputo SL; Bellagamba R; Zaccarelli M; Visco-Comandini U; Antinori A; Narciso P; Ceccherini-Silberstein F; Perno CF
    J Infect Dis; 2008 May; 197(10):1408-18. PubMed ID: 18419549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The suppression of immune activation during enfuvirtide-based salvage therapy is associated with reduced CCR5 expression and decreased concentrations of circulating interleukin-12 and IP-10 during 48 weeks of longitudinal follow-up.
    Carsenti-Dellamonica H; Saïdi H; Ticchioni M; Guillouet de Salvador F; Dufayard Cottalorda J; Garraffo R; Dellamonica P; Durant J; Gougeon ML
    HIV Med; 2011 Feb; 12(2):65-77. PubMed ID: 20500532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamics of drug-resistant HIV-1 in plasma and peripheral blood cells in patients during and after enfuvirtide therapy.
    Poveda E; Briz V; Paraskevis D; Barreiro P; Hatzakis A; Soriano V
    AIDS Res Hum Retroviruses; 2007 Sep; 23(9):1078-82. PubMed ID: 17919101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assay of HIV gp41 amino acid sequence to identify baseline variation and mutation development in patients with virologic failure on enfuvirtide.
    Loutfy MR; Raboud JM; Montaner JS; Antoniou T; Wynhoven B; Smaill F; Rouleau D; Gill J; Schlech W; Brumme ZL; Mo T; Gough K; Rachlis A; Harrigan PR; Walmsley SL
    Antiviral Res; 2007 Jul; 75(1):58-63. PubMed ID: 17196268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of human immunodeficiency virus type 1 gp41 assays for detecting enfuvirtide (T-20) resistance mutations.
    Marcial M; Lu J; Deeks SG; Ziermann R; Kuritzkes DR
    J Clin Microbiol; 2006 Sep; 44(9):3384-7. PubMed ID: 16954280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.